Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Amy R Peck; Agnieszka K Witkiewicz; Chengbao Liu; Ginger A Stringer; Alexander C Klimowicz; Edward Pequignot; Boris Freydin; Thai H Tran; Ning Yang; Anne L Rosenberg; Jeffrey A Hooke; Albert J Kovatich; Marja T Nevalainen; Craig D Shriver; Terry Hyslop; Guido Sauter; David L Rimm; Anthony M Magliocco; Hallgeir Rui

Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Standard

Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. / Peck, Amy R; Witkiewicz, Agnieszka K; Liu, Chengbao; Stringer, Ginger A; Klimowicz, Alexander C; Pequignot, Edward; Freydin, Boris; Tran, Thai H; Yang, Ning; Rosenberg, Anne L; Hooke, Jeffrey A; Kovatich, Albert J; Nevalainen, Marja T; Shriver, Craig D; Hyslop, Terry; Sauter, Guido; Rimm, David L; Magliocco, Anthony M; Rui, Hallgeir.

In: J CLIN ONCOL, Vol. 29, No. 18, 18, 2011, p. 2448-2458.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Peck, AR, Witkiewicz, AK, Liu, C, Stringer, GA, Klimowicz, AC, Pequignot, E, Freydin, B, Tran, TH, Yang, N, Rosenberg, AL, Hooke, JA, Kovatich, AJ, Nevalainen, MT, Shriver, CD, Hyslop, T, Sauter, G, Rimm, DL, Magliocco, AM & Rui, H 2011, 'Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.', J CLIN ONCOL, vol. 29, no. 18, 18, pp. 2448-2458. <http://www.ncbi.nlm.nih.gov/pubmed/21576635?dopt=Citation>

APA

Peck, A. R., Witkiewicz, A. K., Liu, C., Stringer, G. A., Klimowicz, A. C., Pequignot, E., Freydin, B., Tran, T. H., Yang, N., Rosenberg, A. L., Hooke, J. A., Kovatich, A. J., Nevalainen, M. T., Shriver, C. D., Hyslop, T., Sauter, G., Rimm, D. L., Magliocco, A. M., & Rui, H. (2011). Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J CLIN ONCOL, 29(18), 2448-2458. [18]. http://www.ncbi.nlm.nih.gov/pubmed/21576635?dopt=Citation

Vancouver

Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J CLIN ONCOL. 2011;29(18):2448-2458. 18.

Bibtex

@article{69c44a0b78694bd0a547534832145c64,

title = "Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.",

abstract = "To investigate nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) as a marker of prognosis in node-negative breast cancer and as a predictor of response to antiestrogen therapy.",

keywords = "Adult, Humans, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Cohort Studies, Lymphatic Metastasis, Prognosis, Survival Analysis, Disease-Free Survival, Disease Progression, Protein Processing, Post-Translational, Treatment Failure, Phosphorylation, Drug Resistance, Neoplasm, Antineoplastic Agents, Hormonal/pharmacology/therapeutic use, Breast Neoplasms/drug therapy/*metabolism/mortality/pathology, Carcinoma, Ductal, Breast/drug therapy/*metabolism/mortality/pathology, Carcinoma, Intraductal, Noninfiltrating/drug therapy/*metabolism/mortality/pathology, Estrogen Receptor Modulators/pharmacology/therapeutic use, Neoplasm Proteins/chemistry/*physiology, Nuclear Proteins/chemistry/*physiology, Phosphotyrosine/chemistry, STAT5 Transcription Factor/chemistry/*physiology, Tumor Suppressor Proteins/chemistry/*physiology, Adult, Humans, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Cohort Studies, Lymphatic Metastasis, Prognosis, Survival Analysis, Disease-Free Survival, Disease Progression, Protein Processing, Post-Translational, Treatment Failure, Phosphorylation, Drug Resistance, Neoplasm, Antineoplastic Agents, Hormonal/pharmacology/therapeutic use, Breast Neoplasms/drug therapy/*metabolism/mortality/pathology, Carcinoma, Ductal, Breast/drug therapy/*metabolism/mortality/pathology, Carcinoma, Intraductal, Noninfiltrating/drug therapy/*metabolism/mortality/pathology, Estrogen Receptor Modulators/pharmacology/therapeutic use, Neoplasm Proteins/chemistry/*physiology, Nuclear Proteins/chemistry/*physiology, Phosphotyrosine/chemistry, STAT5 Transcription Factor/chemistry/*physiology, Tumor Suppressor Proteins/chemistry/*physiology",

author = "Peck, {Amy R} and Witkiewicz, {Agnieszka K} and Chengbao Liu and Stringer, {Ginger A} and Klimowicz, {Alexander C} and Edward Pequignot and Boris Freydin and Tran, {Thai H} and Ning Yang and Rosenberg, {Anne L} and Hooke, {Jeffrey A} and Kovatich, {Albert J} and Nevalainen, {Marja T} and Shriver, {Craig D} and Terry Hyslop and Guido Sauter and Rimm, {David L} and Magliocco, {Anthony M} and Hallgeir Rui",

year = "2011",

language = "English",

volume = "29",

pages = "2448--2458",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "18",

}

RIS

TY - JOUR

T1 - Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

AU - Peck, Amy R

AU - Witkiewicz, Agnieszka K

AU - Liu, Chengbao

AU - Stringer, Ginger A

AU - Klimowicz, Alexander C

AU - Pequignot, Edward

AU - Freydin, Boris

AU - Tran, Thai H

AU - Yang, Ning

AU - Rosenberg, Anne L

AU - Hooke, Jeffrey A

AU - Kovatich, Albert J

AU - Nevalainen, Marja T

AU - Shriver, Craig D

AU - Hyslop, Terry

AU - Sauter, Guido

AU - Rimm, David L

AU - Magliocco, Anthony M

AU - Rui, Hallgeir

PY - 2011

Y1 - 2011

N2 - To investigate nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) as a marker of prognosis in node-negative breast cancer and as a predictor of response to antiestrogen therapy.

AB - To investigate nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) as a marker of prognosis in node-negative breast cancer and as a predictor of response to antiestrogen therapy.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Cohort Studies

KW - Lymphatic Metastasis

KW - Prognosis

KW - Survival Analysis

KW - Disease-Free Survival

KW - Disease Progression

KW - Protein Processing, Post-Translational

KW - Treatment Failure

KW - Phosphorylation

KW - Drug Resistance, Neoplasm

KW - Antineoplastic Agents, Hormonal/pharmacology/therapeutic use

KW - Breast Neoplasms/drug therapy/metabolism/mortality/pathology

KW - Carcinoma, Ductal, Breast/drug therapy/metabolism/mortality/pathology

KW - Carcinoma, Intraductal, Noninfiltrating/drug therapy/metabolism/mortality/pathology

KW - Estrogen Receptor Modulators/pharmacology/therapeutic use

KW - Neoplasm Proteins/chemistry/physiology

KW - Nuclear Proteins/chemistry/physiology

KW - Phosphotyrosine/chemistry

KW - STAT5 Transcription Factor/chemistry/physiology

KW - Tumor Suppressor Proteins/chemistry/physiology